PET imaging of early response to the tyrosine kinase inhibitor ZD4190
- 1 March 2011
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 38 (7), 1237-1247
- https://doi.org/10.1007/s00259-011-1742-z
Abstract
We evaluated noninvasive positron emission tomography (PET) imaging for monitoring tumor response to the VEGFR-2 tyrosine kinase (TK) inhibitor ZD4190 during cancer therapy.Keywords
This publication has 48 references indexed in Scilit:
- 18F-FPPRGD2 and 18F-FDG PET of Response to Abraxane TherapyJournal of Nuclear Medicine, 2010
- Molecular imaging in cancer treatmentEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- 18F-Labeled Galacto and PEGylated RGD Dimers for PET Imaging of αvβ3 Integrin ExpressionMolecular Imaging & Biology, 2009
- Noninvasive Imaging of αVβ3 Function as a Predictor of the Antimigratory and Antiproliferative Effects of DasatinibCancer Research, 2009
- Use of a Novel Arg-Gly-Asp Radioligand,18F-AH111585, to Determine Changes in Tumor Vascularity After Antitumor TherapyJournal of Nuclear Medicine, 2008
- Early Detection of Chemoradioresponse in Esophageal Carcinoma by 3′-Deoxy-3′-3H-Fluorothymidine Using Preclinical Tumor ModelsClinical Cancer Research, 2006
- Measures of Response: RECIST, WHO, and New AlternativesJournal of Clinical Oncology, 2006
- Multimodality Tumor Imaging Targeting Integrin α v β 3BioTechniques, 2005
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971
- On the Origin of Cancer CellsScience, 1956